Chabiotech Co.,Ltd. (085660.KQ)
KRW 15280.0
(-2.98%)
KRW 15280.0
(-2.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.42 Billion KRW | 82.44% |
| 2022 | -53.66 Billion KRW | -938.93% |
| 2021 | 6.39 Billion KRW | 215.95% |
| 2020 | -5.51 Billion KRW | -226.84% |
| 2019 | 4.34 Billion KRW | -75.94% |
| 2018 | 18.07 Billion KRW | 282.38% |
| 2017 | -9.91 Billion KRW | -125.18% |
| 2016 | 39.36 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -776.91 Million KRW | 93.84% |
| 2024 Q1 | -12.6 Billion KRW | 30.04% |
| 2023 FY | -9.42 Billion KRW | 82.44% |
| 2023 Q2 | 1.57 Billion KRW | -86.97% |
| 2023 Q3 | -5.05 Billion KRW | -421.29% |
| 2023 Q4 | -18.01 Billion KRW | -256.53% |
| 2023 Q1 | 12.07 Billion KRW | 144.39% |
| 2022 Q2 | -5.52 Billion KRW | -6.83% |
| 2022 FY | -53.66 Billion KRW | -938.93% |
| 2022 Q4 | -27.2 Billion KRW | -72.5% |
| 2022 Q3 | -15.77 Billion KRW | -185.61% |
| 2022 Q1 | -5.16 Billion KRW | -379.28% |
| 2021 Q4 | 1.85 Billion KRW | 689.53% |
| 2021 FY | 6.39 Billion KRW | 215.95% |
| 2021 Q3 | 234.43 Million KRW | 0.0% |
| 2020 FY | -5.51 Billion KRW | -226.84% |
| 2019 FY | 4.34 Billion KRW | -75.94% |
| 2018 FY | 18.07 Billion KRW | 282.38% |
| 2017 FY | -9.91 Billion KRW | -125.18% |
| 2016 FY | 39.36 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 92.461% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -186.92% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 1004.3% |
| Bioneer Corporation | 791.75 Million KRW | 1290.421% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -85.76% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 62.495% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 69.511% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 73.258% |
| Medy-Tox Inc. | 17.32 Billion KRW | 154.411% |
| Peptron, Inc. | -15.6 Billion KRW | 39.593% |
| Amicogen, Inc. | 2.05 Billion KRW | 558.392% |
| Genexine, Inc. | -41.24 Billion KRW | 77.146% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -8.332% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 88.338% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 3.201% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 109.349% |
| SillaJen, Inc. | -21.34 Billion KRW | 55.845% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 457.877% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 48.171% |
| Genomictree Inc. | -17.3 Billion KRW | 45.53% |
| MedPacto, Inc. | -28.75 Billion KRW | 67.219% |
| D&D Pharmatech | -13.48 Billion KRW | 30.113% |
| EASY BIO,Inc. | 20.63 Billion KRW | 145.684% |
| GI Innovation, Inc. | -55.6 Billion KRW | 83.049% |